Another active, but not recruiting, Phase 2 trial is evaluating the efficacy of an MVA EBNA1/LMP2 vaccine in patients with persistent, recurrent or metastatic nasopharyngeal cancer (NCT01094405, Table 1). Here, PSMB9 is linked to nasopharyngeal carcinoma.